Pfizer (PFE) Other Non-Current Liabilities (2009 - 2026)

Pfizer (PFE) has 18 years of Other Non-Current Liabilities data on file, last reported at $3.7 billion in Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $3.7 billion, down 35.27% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.7 billion (down 35.27% YoY), and the FY2025 annual result was $3.6 billion, down 41.25% from the prior year.
• Other Non-Current Liabilities climbed to $3.7 billion in Q1 2026 per PFE's latest filing, from $3.6 billion in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $16.1 billion in Q2 2024 and troughed at $3.6 billion in Q4 2025.
• A 5-year average of $9.4 billion and a median of $8.6 billion in 2024 frame the typical range for Other Non-Current Liabilities.
• On a YoY basis, Other Non-Current Liabilities climbed as much as 130.4% in 2025 and fell as far as 41.25% in 2025.
• A 5-year view of Other Non-Current Liabilities shows it stood at $13.2 billion in 2022, then slumped by 35.25% to $8.5 billion in 2023, then fell by 28.38% to $6.1 billion in 2024, then tumbled by 41.25% to $3.6 billion in 2025, then increased by 3.17% to $3.7 billion in 2026.
• Business Quant data shows PFE's Other Non-Current Liabilities at $3.7 billion in Q1 2026, $3.6 billion in Q4 2025, and $13.6 billion in Q3 2025.